- Home
- SGC vs LUNG Comparison
SGC vs LUNG Comparison
Compare SGC & LUNG Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- SGC
- LUNG
- Stock Information
- Founded
- SGC 1920
- LUNG 1995
- Country
- SGC United States
- LUNG United States
- Employees
- SGC N/A
- LUNG N/A
- Industry
- SGC Apparel
- LUNG Industrial Specialties
- Sector
- SGC Consumer Discretionary
- LUNG Health Care
- Exchange
- SGC Nasdaq
- LUNG Nasdaq
- Market Cap
- SGC 215.7M
- LUNG 65.6M
- IPO Year
- SGC N/A
- LUNG 2020
- Fundamental
- Price
- SGC $11.79
- LUNG $1.70
- Analyst Decision
- SGC Strong Buy
- LUNG Buy
- Analyst Count
- SGC 3
- LUNG 7
- Target Price
- SGC $17.33
- LUNG $7.66
- AVG Volume (30 Days)
- SGC 41.6K
- LUNG 574.6K
- Earning Date
- SGC 11-05-2025
- LUNG 10-29-2025
- Dividend Yield
- SGC 4.75%
- LUNG N/A
- EPS Growth
- SGC N/A
- LUNG N/A
- EPS
- SGC 0.52
- LUNG N/A
- Revenue
- SGC $576,240,000.00
- LUNG $90,549,000.00
- Revenue This Year
- SGC $1.46
- LUNG $10.30
- Revenue Next Year
- SGC $3.32
- LUNG $14.72
- P/E Ratio
- SGC $22.59
- LUNG N/A
- Revenue Growth
- SGC 4.03
- LUNG 18.24
- 52 Week Low
- SGC $9.11
- LUNG $1.47
- 52 Week High
- SGC $18.48
- LUNG $9.37
- Technical
- Relative Strength Index (RSI)
- SGC 46.13
- LUNG 43.79
- Support Level
- SGC $11.60
- LUNG $1.60
- Resistance Level
- SGC $12.27
- LUNG $1.80
- Average True Range (ATR)
- SGC 0.45
- LUNG 0.14
- MACD
- SGC -0.19
- LUNG 0.04
- Stochastic Oscillator
- SGC 8.72
- LUNG 36.67
About SGC Superior Group of Companies Inc.
Superior Group Of Companies Inc designs apparel products. The company's operating segment includes Branded Products; Healthcare Apparel and Contact Centers. It generates maximum revenue from the Branded Products segment. The Branded Products segment produce and sell customized merchandising solutions, promotional products and branded uniform programs to customers.
About LUNG Pulmonx Corporation
Pulmonx Corp is a commercial-stage medical technology company. It provides a minimally invasive treatment for patients with severe emphysema, a form of chronic obstructive pulmonary disease (COPD). The company's solutions are comprised of the Zephyr Endobronchial Valve, the Chartis Pulmonary Assessment System and the StratX Lung Analysis Platform. It generates revenue through the sale of products to distributors and hospitals in the United States which a key revenue generating market, Europe, Middle-East and Africa, Asia Pacific and other regions.